ArticleJournal of translational medicine2025
Verteporfin, an inhibitor of nuclear YAP, improved multi-ciliated cell differentiation in the airway epithelium.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImpaired multi-ciliated cell (MCC) differentiation, observed in various airway diseases, causes prolonged inflammation and further airway complications due to malfunction of the airway defense mechanism. YAP/TAZ-TEAD signaling mediates multiple mechanisms associated with MCC differentiation. However, YAP reportedly has both negative and positive roles in MCC differentiation, putatively due to its dual functions in the cytoplasm and nucleus. We hypothesize inhibition of nuclear YAP, while preserving cytoplasmic YAP functions, restores MCCs in various airway disorders. Here, we investigated the relationship between YAP nuclear localization and the presence of MCCs across patients. In addition, we identified compounds that promote MCC differentiation based on the inhibitory function of YAP nuclear localization.
methodTracheal specimens were collected from patients with different conditions (smoking, irradiation, tracheotomy, dysphagia), and YAP nuclear localization in MCCs was assessed by immunohistochemistry at areas with varying MCC compositions. To identify compounds that efficiently inhibit nuclear localization of YAP, airway epithelial cells were treated with multiple YAP inhibitors and YAP nuclear localization was assessed by immunofluorescence-based image analysis. The effects of the compounds on MCC differentiation were evaluated using air-liquid interface (ALI) culture and rat airway squamous metaplasia models.
resultsIn the human trachea, YAP nuclear localization in MCCs was negatively correlated with the proportion of MCCs in the epithelium, regardless of patient condition. Among known YAP inhibitors, verteporfin and atorvastatin efficiently inhibited YAP nuclear localization in cultured airway epithelial cells. Additionally, verteporfin promoted MCC differentiation in ALI culture and in vivo squamous metaplasia models.
conclusionOur findings suggest YAP nuclear localization in human airway MCCs is broadly associated with decreased MCCs regardless of patient condition, and verteporfin improves airway MCC differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.